Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2407816 | Vaccine | 2007 | 9 Pages |
Abstract
We used a replication-incompetent, single-cycle, alphavirus replicon vector system to produce virus-like replicon particles (VRP) expressing the extracellular domain of human cytomegalovirus (CMV) glycoprotein B or a pp65/IE1 fusion protein. Efficient production methods were scaled to produce pilot lots and clinical lots of each alphavirus replicon vaccine component. The vaccine induced high-titered antibody responses in mice and rabbits, as measured by ELISA and CMV neutralization assays, and robust T-cell responses in mice, as measured by IFN-γ ELISPOT assay. A toxicity study in rabbits showed no adverse effects in any toxicology parameter. These studies support clinical testing of this novel CMV alphavirus replicon vaccine in humans.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Elizabeth A. Reap, John Morris, Sergey A. Dryga, Maureen Maughan, Todd Talarico, Robert E. Esch, Sarah Negri, Bruce Burnett, Andrew Graham, Robert A. Olmsted, Jeffrey D. Chulay,